Please use this identifier to cite or link to this item: https://www.arca.fiocruz.br/handle/icict/30442
Title: Prognostic Relevance of KITand PDGFRAMutations in Gastrointestinal Stromal Tumors
Authors: Braggio, Esteban
Braggio, Danielle de Almeida
Small, Isabele Ávila
Lopes, Lisandro F.
Valadão, Marcus
Gouveia, Maria Emmerick
Moreira, Aline dos Santos
Linhares, Eduardo
Romano, Sérgio
Bacchi, Carlos E.
Renault, Ilana Zalcherg
Guimarães, Denise Peixoto
Ferreira, Carlos Gil
Affilliation: Instituto Nacional de Câncer. Centro de Transplante de Medula Óssea. Rio de Janeiro, RJ, Brasil.
Instituto Nacional de Câncer. Divisão de Pesquisa Clínica. Rio de Janeiro, RJ, Brasil.
Instituto Nacional de Câncer. Divisão de Pesquisa Clínica. Rio de Janeiro, RJ, Brasil.
Consultoria em Patologia. Botucatu, SP, Brasil.
Instituto Nacional de Câncer. Serviço de Cirurgia Abdominal-pélvica. Rio de Janeiro, RJ, Brasil.
Instituto Nacional de Câncer. Centro de Transplante de Medula Óssea. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Genômica Funcional de Bioinformática. Rio de Janeiro, RJ, Brasil.
Instituto Nacional de Câncer. Serviço de Cirurgia Abdominal-pélvica. Rio de Janeiro, RJ, Brasil.
Instituto Nacional de Câncer. Divisão de Patologia. Rio de Janeiro, RJ, Brasil.
Consultoria em Patologia. Botucatu, SP, Brasil.
Instituto Nacional de Câncer. Centro de Transplante de Medula Óssea. Rio de Janeiro, RJ, Brasil.
Instituto Nacional de Câncer. Divisão de Pesquisa Clínica. Rio de Janeiro, RJ, Brasil.
Instituto Nacional de Câncer. Centro de Transplante de Medula Óssea. Rio de Janeiro, RJ, Brasil.
Abstract: Background: Prediction of biological behavior is crucial for selection of new therapeutic modalities in GIST. Here, we aimed to assess whether KIT and PDGFRA mutations have survival impact in gastrointestinal stromal tumors (GIST). Patients and Methods: Fifty-five Brazilian patients with completely resected GIST were examined for KIT and PDGFRA mutations. The 5-year disease-free survival (DFS) was analyzed. Results: KIT and PDGFRA mutations were identified in 74.5% and 7.3% of patients, respectively. The 5-year DFS rate for all patients was 52.8%. The 5-year DFS rate was lower in patients with tumors having inframe deletions or concomitant in-frame deletions and insertions affecting codons 557-558 than in patients with tumors having other exon 11 KIT mutations (p=0.023). Conversely, when the patients with concomitant deletioninsertion mutations affecting codons 557-558 were excluded from the analysis, deletions involving codons 557-558 had no influence on 5-year DFS rates. Conclusion: Our findings indicate that a specific KIT mutation may be associated with unfavorable behavior in GIST. This finding may have implications on selecting patients for adjuvant therapy.
Keywords: Gastrointestinal Stromal Tumors
mutations
Prognostic Relevance
KIT and PDGFRA mutations
keywords: Relevância prognóstica
tumores estromais gastrointestinais
mutações do KIT e PDGFRA
Issue Date: 2010
Publisher: International Institute of Anticancer Research
Citation: BRAGGIO, Esteban; et al. Prognostic Relevance of KITand PDGFRAMutations in Gastrointestinal Stromal Tumors. Anticancer Research, v.30, p.2407-2414, 2010.
ISSN: 0250-7005
Copyright: open access
Appears in Collections:IOC - Artigos de Periódicos

Files in This Item:
File Description SizeFormat 
alines_moreira_etal_IOC_2010.pdf206.71 kBAdobe PDFView/Open


FacebookTwitterDeliciousLinkedInGoogle BookmarksBibTex Format mendeley Endnote DiggMySpace

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.